首页> Journal for immunotherapy of cancer> Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates.

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates.

导出 LinkOut

翻译打印收藏纠错

第一作者： John B,Liao

第一单位： University of Washington School of Medicine, Seattle, Washington, USA johnliao@uw.edu.

作者： John B,Liao ^[1] ; William R,Gwin ^[2] ; Renata R,Urban ^[2] ; Katie M,Hitchcock-Bernhardt ^[2] ; Andrew L,Coveler ^[2] ; Doreen M,Higgins ^[2] ; Jennifer S,Childs ^[2] ; Hania N,Shakalia ^[2] ; Ron E,Swensen ^[3] ; Sasha E,Stanton ^[4] ; Anna V,Tinker ^[5] ; Tanya A,Wahl ^[6] ; Richard G,Ancheta ^[7] ; Kathryn F,McGonigle ^[2] ; James Y,Dai ^[8] ; Mary L,Disis ^[2] ; Barbara A,Goff ^[2]

作者单位： University of Washington School of Medicine, Seattle, Washington, USA johnliao@uw.edu. ^[1] University of Washington School of Medicine, Seattle, Washington, USA. ^[2] Valley Medical Center, Renton, Washington, USA. ^[3] Providence Cancer Center, Portland, Oregon, USA. ^[4] BC Cancer Agency, Vancouver, British Columbia, Canada. ^[5] Swedish Medical Center, Seattle, Washington, USA. ^[6] Kaiser Permanente, Seattle, Washington, USA. ^[7] Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. ^[8]

关键词 CD8-positive t-lymphocytes combination drug therapy female genital neoplasms immunotherapy